Related by context. All words. (Click for frequent words.) 70 confirmatory clinical 68 PRIMO CABG 67 ThermoDox ® clinical 66 MEND CABG 66 phase IIb clinical 66 phase IIb study 66 randomized Phase 2b 66 MEND CABG II 66 ToGA 66 evaluating mipomersen 66 BRIM2 65 opioid induced bowel dysfunction 65 STRIDE PD 65 NSABP C 65 BRIM3 65 alvespimycin 65 ABSORB trial 65 EMPOWER ™ 65 HCV RESPOND 2 65 randomized controlled multicenter 65 Entereg R 65 Telik logo TELINTRA 65 pivotal bioequivalence 65 TEMSO 65 number NCT# ClinicalTrials.gov 65 pharmacokinetic PK 64 Phase Ib clinical 64 trastuzumab emtansine T DM1 64 EDEMA3 trial 64 Phase 1b clinical trials 64 APEX AMI trial 64 elotuzumab 64 TRA 2P 64 riociguat 64 AVOREN 64 ENRICH trial 64 ORAL Solo 64 Phase 1a clinical 64 Phase Ib II 64 ExTRACT TIMI 64 subcutaneous PRO 64 recombinant PSMA vaccine 64 Val HeFT 64 tramiprosate Alzhemed TM 64 phase Ib 64 phase IIa clinical 64 PANVAC VF 64 SYMMETRY trial 63 MERLIN TIMI 63 prospectively defined 63 NO# [002] 63 Carotid Revascularization Endarterectomy vs. 63 lintuzumab SGN 63 CLIRS trial 63 teriflunomide 63 multicenter Phase II 63 MIST II 63 phase IIa 63 INCB# [001] 63 MAGE A3 ASCI 63 placebo controlled clinical 63 pharmacodynamic effects 63 phase IIb trial 63 PFO migraine 63 PARTNER Trial 63 Phase IIB 63 CHAMPION PCI 63 Phase Ib study 63 PCI ExTRACT TIMI 63 REMINYL ® 63 AVERROES 63 DSMB recommended 63 XL# SAR# 63 placebo controlled multicenter 63 SUCCEED trial 63 XL# XL# XL# XL# 63 Octreolin 63 TAXUS IV 63 AVADO 63 budesonide foam 63 Subgroup analysis 62 Xelox 62 GAMMAGARD 62 dose escalation phase 62 Maximum Tolerated Dose MTD 62 Primary endpoints 62 pharmacodynamic PD 62 albiglutide 62 rALLy clinical trial 62 evaluating T DM1 62 LungAlert TM 62 malignant mesothelioma Alfacell 62 treatment naive genotype 62 multicenter Phase 62 SPIRIT FIRST 62 CALGB # [002] 62 Androxal TM 62 ongoing Phase 1b 62 Phase IIb III 62 SPIRIT III 62 morphometric vertebral fractures 62 trastuzumab DM1 T DM1 62 secondary efficacy endpoint 62 ATACAND 62 subgroup analyzes 62 compound INCB# 62 lesinurad 62 Committee IDMC 62 PEARL SC 62 APPRAISE 62 Xanafide 62 eritoran 62 EXPLORE Xa 62 HCV SPRINT 62 CARE HF 62 evaluating Actimmune 62 ADMIRE HF 62 R# #mg BID 62 MADIT II 62 nonrandomized 62 granted Ortec 62 CRMD# 62 recurrent malignant glioma 62 PI3K/Akt pathway inhibitor 62 EDEMA4 trial 62 LUX Lung 62 initiate multicenter 62 HORIZONS AMI trial 62 SIMPADICO 62 EDEMA3 62 EDEMA4 62 serum phosphorous 62 NATRECOR ® 62 ABSORB clinical 62 Urocortin 2 62 pexelizumab 62 ELACYT 62 Sibutramine Cardiovascular Outcomes 62 FOLFOX6 chemotherapy regimen 62 Phase 2b study 62 catheter occlusion 62 phase IIIb 62 Edge STudy 62 evaluating intravenous picoplatin 62 rash pruritus nausea 62 axitinib 62 cardiovascular hospitalizations 62 TOLAMBA 62 Phase #/#a 62 ENDEAVOR III 62 RE LY 62 Phase III metastatic melanoma 62 oral deforolimus 62 oral ridaforolimus 62 XL# anticancer compounds 61 Phase IIb trials 61 Pharmacokinetic parameters 61 bevirimat Study 61 ILLUMINATE 61 ENABLE Phase 2 61 symptomatic VTE 61 neratinib 61 COU AA 61 vosaroxin 61 ACCORD Lipid 61 CYT# potent vascular disrupting 61 PLX STROKE targeting 61 ANCHOR trial 61 registrational Phase 61 Phase III VISTA 61 PRECISE trial 61 rALLy trial 61 randomized discontinuation trial 61 deforolimus 61 galiximab 61 Telintra 61 DASISION 61 CTAP# Capsules 61 PRE SURGE 61 Evidence Therapeutic 61 phase IIb 61 urocortin 2 61 Prostate AdenoCarcinoma Treatment 61 RECORD1 61 mertansine 61 Bayer HealthCare Onyx Pharmaceuticals 61 AVN# Phase 61 Phase #b/#a clinical 61 formal pharmacokinetic PK 61 secondary efficacy endpoints 61 GENASIS trial 61 opioid naive 61 Diamyd r vaccine 61 INSPIRE Trial Phase III 61 relapsed MM 61 Zemplar Capsules 61 European Sepsis Trial 61 ROCKET AF 61 intravenous RSD# 61 Aflibercept 61 recurrent metastatic ovarian cancer 61 cancer neuroendocrine tumor 61 HGS ETR2 61 Phase IIIb clinical 61 visilizumab 61 confirmatory pivotal 61 Phase IIb randomized 61 LymphoStat B belimumab 61 Empatic ™ 61 PITX2 methylation 61 phase III ACCLAIM 61 varespladib 61 omecamtiv mecarbil 61 ENDEAVOR IV 61 phase 2a 61 evaluating REVLIMID 61 IMPACT DCM clinical 61 tumor progression TTP 61 Proellex TM 61 Genasense ® oblimersen 61 nonclinical studies 61 TAXUS VI 60 placebo controlled Phase 60 Budesonide foam crofelemer 60 CHD CVD 60 Phase #b/#a 60 Curaxin CBLC# 60 REVIVE TA 60 ALSYMPCA 60 EVEREST II 60 recurrent glioblastoma multiforme 60 ALN VSP Phase 60 Hematide ™ peginesatide 60 LibiGel ® testosterone gel 60 oral prodrug 60 midstage trials 60 Phase Ib clinical trials 60 drug figitumumab 60 IMPACT DCM 60 ancrod 60 please visit www.advaxis.com 60 EMPOWER TM 60 bicifadine 60 virus HCV protease inhibitor 60 ularitide 60 ENESTnd 60 includes TOLAMBA TM 60 fosbretabulin 60 specified secondary endpoints 60 CIMZIA TM certolizumab pegol 60 ocrelizumab 60 initiated confirmatory Phase 60 Phase 1b trial 60 randomized Phase IIb 60 REVIVE Diabetes 60 torcetrapib atorvastatin 60 adecatumumab 60 multicenter Phase III 60 Exelixis compounds 60 Phase III AFFIRM 60 systemic Phase 1b 60 dose escalation Phase 60 kidney urologic 60 cangrelor 60 pain palliation 60 PROSTVAC ® 60 By JENNIFER LEARN 60 Crofelemer budesonide foam 60 CUSTOM III 60 PROSTVAC VF 60 targeting miR 60 midstage clinical 60 QTc prolongation 60 Vitaxin 60 BR.# 60 IMPACT IMmunotherapy 60 RE LY ® 60 GRNCM1 60 Tarceva TM 60 ruxolitinib 60 NYHA Class II 60 R lenalidomide 60 Entereg TM 60 clazosentan 60 landmark ATHENA 60 Nasdaq PGNX today 60 novel VDA molecule 60 CAMMS# 60 Phase IIIb 60 GOUT 60 Hematide ™ 60 romidepsin 60 huC# DM4 60 LibiGel Phase III 60 XmAb# 60 evaluating tivozanib 60 Phase 2a trial 60 pressure tachycardia diaphoresis 60 Phase 2b kidney transplant 60 Plicera 60 Phase Ib IIa 60 Erythropoietic therapies may 60 Ribavirin causes 60 imatinib therapy 60 AIM HIGH 60 Phase III ThermoDox 60 Motesanib 60 PROactive study 60 blinded randomized placebo controlled 60 tremelimumab 60 bepotastine besilate nasal spray 60 Triapine R 60 dimebon latrepirdine 60 undergoing elective percutaneous 60 Aurexis 60 modified REGENESIS Phase IIb 60 headache nasopharyngitis 60 adjuvant GIST 60 neurologic progression 60 multicenter placebo controlled 60 assessing T DM1 60 ongoing Phase IIIb 60 pharmacokinetics PK 60 cannabinor 60 EchoCRT 60 motesanib 60 Dextofisopam 60 confirmatory Phase III 60 Phase III confirmatory 59 RIO Diabetes 59 randomized controlled Phase 59 Augment Injectable 59 CINQUIL 59 drug pipeline TAFA# 59 RSD# oral 59 ENMD # 59 BCIRG 59 elacytarabine 59 baminercept 59 Phase IIb clinical trials 59 alvimopan 59 GSK# [001] 59 IV RSD# 59 JAK inhibitor 59 arzoxifene 59 www.telik.com 59 registrational 59 Zevalin consolidation 59 Bezielle 59 bazedoxifene conjugated estrogens 59 APEX PD 59 EMPHASIS HF trial 59 Panzem R 59 preclinical efficacy 59 angiographic outcomes 59 Auxilium anticipates 59 figitumumab 59 CAPACITY trials 59 oxymorphone ER 59 tolerated dose MTD 59 Initiated Phase 59 forodesine 59 TAXUS V 59 evaluating bafetinib 59 oral FTY# 59 SYMMETRY SM trial 59 prospective multicenter randomized 59 brivaracetam 59 develop HBV reactivation 59 coronary stent merged 59 Canvaxin TM 59 sNDA submission 59 CIMZIA ™ 59 HDL Selective Delipidation 59 Phase III ADT 59 successfully commercialize Iluvien 59 Dose Limiting Toxicity DLT 59 metastatic castration resistant 59 ENDEAVOR II 59 Celacade TM technology 59 ACCLAIM trial 59 VITAL Trial 59 maximally tolerated dose 59 SPIRIT IV 59 PF # [002] 59 please visit http:/www.sunesis.com 59 PROSTVAC TM 59 Glufosfamide 59 controlled multicenter Phase 59 rosuvastatin #mg 59 CURE AF 59 GEM OS2 59 Zenvia ™ 59 TransVax 59 aplindore 59 PSMA ADC 59 pharmacodynamics PD 59 thorough QT 59 Phase 2a clinical 59 PROTECT AF 59 ADHF 59 unstable angina pectoris 59 clinical trials SGN 59 PROactive Study 59 Ocrelizumab 59 Azedra 59 Genz # 59 papillary renal cell carcinoma 59 HuMax EGFr 59 Cloretazine ® 59 Cimzia TM 59 nalbuphine ER 59 enoximone 59 viral kinetic 59 #/#/# Cytokinetics Incorporated 59 HGS ETR1 mapatumumab 59 ARCOXIA 59 Second Pivotal Phase 59 PRECISE Trial 59 eprotirome 59 evaluating Vectibix 59 r hGH 59 MIVI TRUST 59 candidate XP# 59 Phase III HEAT 59 Cinquil 59 OvaRex ® MAb 59 Secondary efficacy endpoints 59 Prestara 59 Thalomid ® 59 Phase IIIb study 59 thromboembolic complications 59 hyperphenylalaninemia HPA due 59 PROTECT II 59 Aplidin 59 desvenlafaxine succinate 59 COMFORT II 59 EOquin TM phase 59 ACTEMRA TM 59 lomitapide 59 demonstrated antitumor activity 59 Initiates Phase II 59 TASKi2 59 Phase 1b 59 multicenter randomized placebo controlled 59 XIENCE V PROMUS Stent 59 Romiplostim 59 Active Ulcerative Colitis 59 chronic thromboembolic pulmonary 59 YONDELIS 59 please visit http:/www.atherogenics.com 59 Long Lesion 59 Asentar 59 avosentan 59 Amigal TM 59 oral picoplatin 59 PEGylated interferon beta 1a 59 Genentech Wyeth Pharmaceuticals 59 adecatumumab MT# 59 CALGB 59 evaluating satraplatin 59 dexanabinol 59 Initiates Enrollment 59 NEO3 59 Rigel R# 59 metastatic HRPC 59 budesonide MMX Phase III 59 SORT OUT III 59 metaglidasen 59 Oral NKTR 59 dose escalation trial 59 bardoxolone 59 Pivotal Phase 59 PROPEL trial 59 ONTARGET 59 multicenter randomized controlled 59 neurogenic orthostatic hypotension 59 Anturol TM 59 Quinamed 59 Initiate Phase 59 OncoVex 59 olaparib 59 ReN# 58 intravesical infusion therapy 58 myocardial infarction ventricular fibrillation 58 VADT 58 TRIOLEX HE# APOPTONE HE# 58 Dose escalation 58 candidate CRLX# 58 randomized Phase III 58 PROMACTA 58 enzastaurin 58 MYTHOS trial 58 cerebrovascular events 58 MKC# MKC# PP 58 MGd 58 Randomized Double blind 58 ataluren 58 Fibrillex TM 58 ORACLE MS 58 BrachySil TM 58 sitaxsentan 58 tesmilifene 58 lintuzumab 58 Meta analyzes 58 solid tumors ZYBRESTAT 58 multicentre randomized 58 Airvana anticipates 58 ZYBRESTAT fosbretabulin 58 Sepracor anticipates 58 NATRECOR R 58 retinal vein occlusion induced 58 GetGoal Phase III 58 dirucotide 58 By LEO SHANE 58 NEUVENGE 58 placebo controlled clinical trials 58 KIF6 carriers 58 PMX # heptagonist 58 novel therapeutic antibodies 58 deCODE AF TM 58 Oral Calcitonin 58 pertuzumab 58 Genasense R oblimersen 58 Achieves Primary Endpoint 58 Evidence Therapeutic study 58 Pivotal Trial 58 MEK inhibitor RDEA# 58 Deforolimus 58 torsemide ER 58 Corlux 58 intradialytic hypotension IDH 58 PROVENGE ® 58 ASSERT trial 58 octreotide implant 58 Tocosol Paclitaxel 58 Allovectin 7 ® 58 unique alkylating agent 58 BLOOM Behavioral modification 58 Phase III Pivotal 58 severe hypercholesterolemia 58 CB2 selective receptor agonist 58 TAXUS Express Stent 58 TAXUS TM 58 didanosine associated 58 oral rivaroxaban 58 efficacy endpoint 58 Phase IIa trial 58 HER2 expression 58 zileuton IV 58 BLOOM DM 58 Dacogen injection 58 IIa trial 58 HGS# 58 OBPM 58 alpha#beta# integrin 58 CCR5 mAb 58 senicapoc 58 Exherin TM 58 rolofylline 58 AIR CF2 58 ORAL Sync 58 OvaRex R 58 Non inferiority 58 Pivotal Phase III 58 azilsartan medoxomil 58 ADVANCE PD 58 UPLYSO 58 PROVENGE sipuleucel T 58 prospective multicentre 58 apremilast 58 DU #b 58 plus prednisone prednisolone 58 zanolimumab 58 clinical trials dacetuzumab SGN 58 ZOLINZA 58 By JAMES JOYCE 58 INCB# [003] 58 multicenter prospective 58 systemically administered 58 GENASIS clinical 58 muraglitazar 58 gefitinib Iressa 58 refractory chronic lymphocytic 58 OPT CHF 58 preclinical pharmacokinetic 58 cardiac myosin activator omecamtiv 58 endothelin antagonists 58 ruboxistaurin 58 p# biomarker 58 rNAPc2 58 dacetuzumab 58 post operative ileus 58 dose titration 58 demonstrated clinically meaningful 58 ProSavin 58 FOLOTYN ® 58 HCD# [002] 58 composite endpoint 58 vaccine GMK 58 Arterial stiffness 58 placebo controlled dose escalation 58 intravascular hemolysis 58 pomalidomide 58 randomized multicenter Phase III 58 placebo controlled Phase III 58 huN# DM1 58 AIR2 Trial 58 davunetide intranasal AL 58 SinuNase TM 58 SILENOR 58 abysmal Shaiken 58 Vascugel 58 Aryplase 58 Hedgehog Pathway Inhibitor 58 coinfected patients 58 dipyridamole plus 58 events thrombocytopenia neutropenia 58 IIa clinical 58 trastuzumab Herceptin R 58 PREOS R 58 website http:/www.npsp.com 58 Multicenter Automatic Defibrillator Implantation 58 vismodegib 58 brivanib 58 antidepressants fluoxetine 58 trials RCTs 58 achieved statistical significance 58 gallium nitrate 58 evaluating picoplatin 58 Triolex 58 vidofludimus 58 AML MDS 58 dirucotide MBP# 58 ostarine 58 ONCONASE R 58 including eniluracil ADH 58 Archexin 58 PERSEUS 58 tolvaptan 58 candesartan cilexetil 58 BY LAWRENCE LATANE 58 R sorafenib tablets 58 docetaxel Taxotere R 58 CLORETAZINE TM VNP#M 58 docetaxel chemotherapy 58 GVAX ® 58 cardiac repolarization 58 naïve HCV 58 fidaxomicin Phase 3 58 Fx #A 58 TAXUS Stent 58 clevidipine 58 Clinical Antipsychotic Trials 58 Completes Patient Enrollment 58 either acutely decompensated 58 Cloretazine R VNP#M 58 Cervista HPV HR 58 PLCO trial 58 evaluating satraplatin plus 58 indolent follicular non 58 safety tolerability pharmacokinetic 58 mg/m2 cohort 58 GSK# [002] 58 apoptosis inducer 58 Phenoptin 58 Panzem R NCD 58 cobiprostone 58 echocardiographic parameters 58 BY ADRIAN NEMES 58 TACI Ig 58 Phase 1b clinical 58 treatment naïve genotype 58 Thorough QT 58 GATTEX ® 58 Testosterone MDTS ® 58 TO AVOID PREGNANCY WHILE 58 Phase Ib 58 pharmacogenomic translational research 58 IMA# 58 Teriflunomide 58 EndoTAGTM 1 58 Tasigna prolongs 58 YOUR LOCAL ANIMAL SHELTER 58 APTIMA HPV assay 58 asthma immunotherapeutic 58 novel synthetic PEGylated 58 MoxDuo IR 58 AEGR 58 ACCEDE 58 By Nate Delesline 57 Forodesine HCl 57 CCX# 57 dyslipidemia hypertension diabetes 57 initiate Phase 1b 57 Thorough QT Study 57 fidaxomicin Phase 57 relapsed refractory multiple myeloma 57 OMNARIS HFA 57 prospective observational studies 57 NEVO 57 MKC# MT 57 Phase 2a clinical trials 57 torezolid phosphate 57 pharmacodynamic markers 57 unresectable malignant mesothelioma UMM 57 Acute Decompensated Heart Failure 57 Phase III placebo controlled 57 unblinding 57 Pyridorin TM 57 refractory gout 57 TIMI Study Group 57 diabetic neuropathic pain 57 QLT Plug Delivery 57 TELCYTA 57 registrational trial 57 ventricular tachyarrhythmia 57 Trastuzumab DM1 57 XIENCE V demonstrated 57 ragweed allergy immunotherapeutic 57 Telatinib 57 pharmacokinetic PK study 57 dosing cohort 57 TAXUS Liberte Long 57 ICON7 57 Lenocta 57 include ColorectAlert TM 57 By PAYTON TOWNS 57 Idenix anticipates 57 Stedivaze 57 PRT# 57 solanezumab 57 LEUKINE 57 SuperMedia specializes 57 prospectively stratified 57 REG1 57 Ereska 57 Ceplene/IL-2 57 Subgroup analyzes 57 PERSEUS clinical program 57 Combination REOLYSIN R 57 dose escalation clinical 57 bile duct tumor 57 Board DSMB 57 haematologic 57 ocular formulation 57 Xcytrin R 57 TAXUS stent 57 www.cellgenesys.com 57 erlotinib Tarceva ® 57 label dose titration 57 developing ACAPODENE 57 dextromethorphan quinidine 57 NP2 Enkephalin 57 eTag assays 57 Lixivaptan 57 telomerase therapeutic 57 brand ciclesonide HFA 57 Cariprazine 57 followers Patricia Krenwinkle 57 occlusion PAO 57 Phase III randomized controlled 57 investigational humanized monoclonal antibody 57 prospective multicenter 57 BioMAP ® Systems 57 BETAS 57 severe dermatologic toxicities 57 GRAVITAS trial 57 randomized multicenter trial 57 relapsed MCL 57 pediatric malignancies 57 DLTs 57 initiate Phase IIb 57 nab paclitaxel 57 controlled multicenter 57 Vernakalant 57 investigational protease inhibitor 57 Sucampo Pharmaceuticals anticipates 57 Safinamide 57 prednisone prednisolone plus 57 ECASS 57 optimal dosing 57 Novo TTF 57 QTinno TM 57 TMC# C# 57 GERD migraine headaches 57 memantine HCl 57 Achillion anticipates 57 bone marrow reticulin deposition 57 thalidomide Thalomid 57 Phase III multicenter 57 PNP inhibitor 57 zoledronic acid Reclast 57 PSADT 57 statistically significant efficacy 57 preclinically 57 nesiritide 57 pegylated interferon peg IFN 57 APEX AMI 57 Cloretazine 57 intravenous cyclophosphamide 57 dosage regimens 57 ADAGIO study 57 Xcellerated T Cells 57 budiodarone 57 CYP#C# genotype 57 serine protease inhibitor CU# 57 multicenter phase 57 Vectibix panitumumab 57 SYNTAX trial 57 treat chronic sinusitis 57 signal detection CTSD 57 small molecule Hedgehog 57 CHARM Added 57 Randomized Phase 57 recurrent metastatic 57 EXJADE 57 TransVax ™ 57 ZoMaxx 57 HQK 57 Cleviprex TM clevidipine 57 multicenter trials 57 GEM OS1 57 ischemic cardiovascular 57 novel histone deacetylase 57 cediranib 57 RG# ITMN 57 Phase #/#a trial 57 NAbs 57 IIIa inhibitor 57 inhibit platelet function 57 GATTEX ™ 57 STAR WARS ARCHIVES EPISODES 57 Randomized clinical trials 57 http:/www.npsp.com 57 BARI 2D 57 TLK# 57 opioid bowel dysfunction 57 RESTORE CLI trial 57 Emily Blunt shimmered 57 FFR measurements 57 HORIZONS AMI 57 prespecified secondary 57 Excellarate TM 57 CLARITY study 57 darusentan 57 AAG geldanamycin analog 57 LEP ETU 57 HIV HCV coinfected 57 acute PAO 57 USpella 57 ChronVac C 57 paclitaxel poliglumex 57 interferon gamma 1b 57 eliglustat tartrate 57 OvaRex MAb 57 NSABP B 57 weekly subcutaneous injections 57 Atrasentan 57 aclidinium 57 Omacetaxine 57 Inc. NASDAQ NBIX 57 hsCRP levels 57 LymphoStat B TM 57 INS# [001] 57 Intervention Effectiveness 57 AIR CF1 57 PACCE trial 57 EmbraceAC 57 Poly ICLC 57 Targretin capsules 57 elective PCI 57 pralatrexate injection folate analogue 57 Ophena TM 57 Phase IIB clinical 57 PR interval prolongation 57 SABCS 57 Symadex 57 trial evaluating PRX# 57 PDX pralatrexate 57 #rd Annual CTRC 57 Novolimus 57 MoxDuo TM IR 57 adjuvant colon cancer 57 clinico pathological 57 double blinded placebo 57 HeFT 57 Phase IIb clinical 57 Initiates Phase III 57 TAXUS ATLAS 57 ganetespib 57 mecarbil 57 TBC# 57 fluvastatin 57 teplizumab 57 prostate carcinogenesis 57 Lymphoseek ® 57 Endovascular Valve Edge 57 hypoxia activated prodrug 57 PrevOnco 57 taxane resistant 57 intensive lipid lowering 57 QTinno 57 angiotensin analog 57 Viprinex TM 57 targeting refractory relapsing 57 Radical prostatectomy 57 Phase IIa clinical 57 class mGluR5 inhibitor 57 GLP toxicology studies 57 Pivotal Phase II 57 canakinumab 57 First Patient Enrolled 57 GALNS 57 eltrombopag 57 relapsing remitting MS RRMS 57 NEVO RES 57 GVAX R 57 sapacitabine CYC# 57 AKT inhibitor 57 anaphylactic reactions bronchospasm 57 Phase 2b trial 57 Phase 2b randomized 57 AGILECT R 56 AEG# 56 vapreotide acetate 56 PRESEPT study 56 somatostatin analog 56 HCV NS5B polymerase 56 noninferiority 56 oxypurinol 56 tolevamer 56 teduglutide 56 paclitaxel eluting stents 56 fund BioSante LibiGel 56 R#/MEM # 56 Selective Electrochemical Tumor Ablation 56 optimal dosing regimens 56 initiated Phase Ib 56 Saforis 56 Enzastaurin 56 BOLDER II 56 Hepatocellular Carcinoma HCC 56 NEVO ™ 56 adenosine injection 56 HGS ETR1 56 Dr. Kandzari 56 cardiovascular morbidity 56 IRX 2 56 coronary revascularization 56 Tekamlo 56 Phase IIa trials 56 receptor tyrosine kinase inhibitor 56 prespecified 56 EURIDIS 56 non constipating irritable 56 EOquin TM 56 http:/www.repligen.com 56 antiarrhythmic drug 56 visit http:/www.clinicaltrials.gov/ 56 cardiovascular hospitalization 56 IL# PE#QQR 56 glufosfamide 56 Severe hypersensitivity reactions 56 NSABP 56 http:/www.optimerpharma.com 56 peginesatide 56 ponatinib 56 Phase 2b Clinical Trial 56 Canvaxin 56 tecarfarin 56 CORT # 56 TG MV 56 Matrix Phase 2b 56 CYP#A# CYP#D# 56 apricitabine ATC 56 Silodosin 56 briakinumab 56 Starent Networks anticipates 56 lowering triglyceride levels 56 Vascular Annual Meeting 56 genotypic resistance 56 myocardial ischemia 56 Nasdaq MAPP 56 ischemic cardiomyopathy 56 VERTEX PHARMACEUTICALS 56 VEGFR2 inhibitor 56 vaso occlusive crisis 56 icatibant 56 BLA filing 56 Nesiritide 56 www.pranabio.com 56 thromboembolic 56 PSN# [002] 56 lenalidomide Revlimid 56 EDARBI 56 CIMZIA R 56 urinary N telopeptide 56 Tarvacin Anti Cancer